Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Fatty Liver in Inflammatory Bowel Disease (IBD) Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2009 by Tel-Aviv Sourasky Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier:
NCT00855907
First received: March 4, 2009
Last updated: NA
Last verified: March 2009
History: No changes posted

March 4, 2009
March 4, 2009
March 2009
March 2010   (final data collection date for primary outcome measure)
  • inflammation and metabolic status [ Time Frame: first visit ] [ Designated as safety issue: No ]
  • Assessment of Fatty liver [ Time Frame: first visit ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Fatty Liver in Inflammatory Bowel Disease (IBD) Patients
Prevalence of Fatty Liver in Inflammatory Bowel Disease (IBD) Patients and Mechanisms Related to Inflammation and Fatty Liver

Fatty liver is known to be one of the most frequent liver pathologies in IBD patients (35-40%). Despite this fact, there are only few publications that evaluated the prevalence of fatty liver in IBD patients. Moreover, the pathogenesis of this phenomenon in IBD has not been widely investigated.

The paradox of lean patients and fatty liver can be explained by high use of steroids, by rapid weight loss, and by the abundance of TNFα cytokine in IBD patients that causes insulin resistance.

The aim of the study:

To evaluate the frequency of fatty liver in a cohort of IBD patients and to learn its risk factors.

Methods:

One hundred consecutive IBD patients treated at the Tel Aviv Sourasky Medical Center will be recruited.

Patients will fill up a questionnaire regarding their disease, demographic data, other co-morbidities and medications and risk factors for metabolic syndrome.

Each patient will undergo blood examinations in order to assess inflammation, and metabolic status. Fatty liver will be assessed by liver ultra-sonography.

Not Provided
Observational
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples Without DNA
Description:

Blood count and biochemistry tests (such as: Liver and thyroid enzimes,cholesterol, immunology, glucose)

Non-Probability Sample

One hundred consecutive IBD patients treated at the Tel Aviv Sourasky Medical Center will be recruited.

  • Inflammatory Bowel Disease
  • Fatty Liver
Other: clinical evaluation

Patients will fill up a questionnaire regarding their disease, demographic data, other co-morbidities and medications and risk factors for metabolic syndrome.

Each patient will undergo blood examinations in order to assess inflammation, and metabolic status. Fatty liver will be assessed by liver ultra-sonography.

cases
IBD patients above the age of 18 years old, suffering from the disease for at least one year.
Intervention: Other: clinical evaluation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
100
March 2011
March 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • IBD patients above the age of 18 years old, suffering from the disease for at least one year.

Exclusion Criteria:

  • Pregnant women,
  • Patients suffering from ulcerative colitis after total colectomy,
  • HIV patients,
  • Patients suffering from other chronic liver disease,
  • Patients suffering from cancer currently or in the past, OR
  • Patients suffering from any other chronic severe diseases.
Both
18 Years and older
No
Contact: Nitsan Maharshak, MD 972-3-6974282 nitsan_maharshak@walla.com
Israel
 
NCT00855907
TASMC-09-NM-593-CTIL
No
Principle investigator - Gastroenterologist, Tel Aviv Sourasky medical center
Tel-Aviv Sourasky Medical Center
Not Provided
Not Provided
Tel-Aviv Sourasky Medical Center
March 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP